bioRxivBioinformaticsPreprint
Assessment of the Degree of Coincidence between Differentially Expressed Genes in Pancreatic Cancer with and without CAR T Cell treatment.
Alibeth E. Luna-AlveariD, Deiver Suárez-GómeziD, Andrea A. Sanchez-Castro, Alexandra C. Rentas-Echeverria, Mauricio Cabrera‐RíosiD, Clara E. IsazaiD
Abstract
Treatment of cancer with CAR T Cells has steadily become a viable and promising cellular therapy approach in recent years. It is well known that liquid cancers are better suited for this kind of treatment, as opposed to solid cancers. This work focuses on contrasting lists of differentially expressed genes (DEGs) found in pancreatic cancer -a solid cancer-against lists of DEGs found in post-CAR T Cell treatment of pancreatic cancer. It is postulated that the degree of coincidence in these lists could positively correlate with treatment effectiveness. OBAMA, a proprietary mathematical optimization-based analysis pipeline that minimizes user selection bias is employed here to preserve objectivity. The study utilized publicly available microarray experiments. The results indicate overall low degrees of coincidence, which partially support the postulate of this work.
- organism: human
- assay: bulk RNA-seq
- research focus: differential expression
- approach: statistical model
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Enhancing synergy of CAR T cell therapy and oncolytic virus therapy for pancreatic cancer.
Rachel Walker, Pedro E. Navas, … Heiko Enderling·bioRxiv·May 30, 2016
- Overcoming Immunological Resistance Enhances the Efficacy of a Novel anti-tMUC1 CAR T Cell Treatment Against Pancreatic Ductal Adenocarcinoma
M. Yazdanifar, R. Zhou, … P. Mukherjee·CellsPeer-reviewed·Sep 11, 2019
- Tumor cell-intrinsic stress states drive sensitivity to CAR T cell-therapy in pancreatic cancer
Julia Fröse, Evelyn Chen, … Michael T. Hemann·Science AdvancesPeer-reviewed·Oct 2, 2026
- Variation in bulk RNA-seq and estimated cell type proportion using deconvolution when comparing pancreatic cancer samples within the same individual
Rick J. Jansen, Sarah A. Munro, … Hugues Sicotte·medRxiv·May 5, 2025
- Immune responses in pancreatic cancer may be restricted byprevalence of activated regulatory T-cells, dysfunctionalCD8+ T-cells, and senescent T-cells
S. Sivakumar, E. Abu-Shah, … M. Dustin·bioRxiv·Jun 20, 2020
- Combating pancreatic cancer with ovarian cancer cells